Alexandre Wagner Silva Souza

List of Publications by Year
in descending order

70 papers	2,065 citations	279487 23 h-index	253896 43 g-index
73 all docs	73 docs citations	73 times ranked	2648 citing authors

#	Article	IF	Citations
1	2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Annals of the Rheumatic Diseases, 2015, 74, 1799-1807.	0.5	220
2	Diagnostic and classification criteria of Takayasu arteritis. Journal of Autoimmunity, 2014, 48-49, 79-83.	3.0	173
3	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. Rheumatology, 2020, 59, e1-e23.	0.9	128
4	HMGB1 in vascular diseases: Its role in vascular inflammation and atherosclerosis. Autoimmunity Reviews, 2012, 11, 909-917.	2.5	120
5	Antiplatelet Therapy for the Prevention of Arterial Ischemic Events in Takayasu Arteritis. Circulation Journal, 2010, 74, 1236-1241.	0.7	104
6	Sistema imunitÃ¡rio: Parte I. Fundamentos da imunidade inata com Ãªnfase nos mecanismos moleculares e celulares da resposta inflamatÃ³ria. Revista Brasileira De Reumatologia, 2010, 50, 434-447.	0.8	81
7	Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study. Scandinavian Journal of Rheumatology, 2012, 41, 227-230.	0.6	71
8	HELLP Syndrome and Its Relationship with Antiphospholipid Syndrome and Antiphospholipid Antibodies. Seminars in Arthritis and Rheumatism, 2011, 41, 517-523.	1.6	57
9	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. Rheumatology, 2020, 59, 487-494.	0.9	56
10	Are cytokines and chemokines suitable biomarkers for Takayasu arteritis?. Autoimmunity Reviews, 2017, 16, 1071-1078.	2.5	54
11	Neurologic manifestations of antiphospholipid syndrome. Lupus, 2018, 27, 1404-1414.	0.8	49
12	Female gout: clinical and laboratory features. Journal of Rheumatology, 2005, 32, 2186-8.	1.0	47
13	Central nervous system vasculitis in adults: An update. Autoimmunity Reviews, 2017, 16, 123-131.	2.5	45
14	Soluble CD40L is associated with increased oxidative burst and neutrophil extracellular trap release in BehÃ§etâ€™s disease. Arthritis Research and Therapy, 2017, 19, 235.	1.6	43
15	Leflunomida na arterite de Takayasu â€“ Estudo observacional de longo prazo. Revista Brasileira De Reumatologia, 2016, 56, 371-375.	0.8	39
16	Takayasu arteritis: assessment of response to medical therapy based on clinical activity criteria and imaging techniques. Rheumatology International, 2012, 32, 703-709.	1.5	38
17	Giant cell arteritis: a multicenter observational study in Brazil. Clinics, 2013, 68, 317-322.	0.6	36
18	Is serum HMGB1 a biomarker in ANCA-associated vasculitis?. Arthritis Research and Therapy, 2013, 15, R104.	1.6	33

#	Article	IF	Citations
19	Impact of hypertension and hyperhomocysteinemia on arterial thrombosis in primary antiphospholipid syndrome. Lupus, 2007, 16, 782-787.	0.8	32
20	Atherosclerotic plaque in carotid arteries in systemic lupus erythematosus: frequency and associated risk factors. Sao Paulo Medical Journal, 2005, 123, 137-142.	0.4	28
21	Emerging role of high mobility group box 1 in ANCA-associated vasculitis. Autoimmunity Reviews, 2015, 14, 1057-1065.	2.5	27
22	CD4+ T helper cells and regulatory T cells in active lupus nephritis: an imbalance towards a predominant Th1 response?. Clinical and Experimental Immunology, 2017, 191, 50-59.	1.1	27
23	Atypical manifestations in Brazilian patients with neuro-BehÃ§etâ€™s disease. Journal of Neurology, 2012, 259, 1159-1165.	1.8	24
24	Leflunomide in Takayasu arteritis â€“ A long term observational study. Revista Brasileira De Reumatologia, 2016, 56, 371-375.	0.7	23
25	Risk factors for cardiovascular disease and endothelin-1 levels in Takayasu arteritis patients. Clinical Rheumatology, 2009, 28, 379-383.	1.0	22
26	Autoantibodies in Systemic Vasculitis. Frontiers in Immunology, 2015, 6, 184.	2.2	22
27	M2 macrophage is the predominant phenotype in airways inflammatory lesions in patients with granulomatosis with polyangiitis. Arthritis Research and Therapy, 2017, 19, 100.	1.6	22
28	Diagnostic power and clinical impact of exome sequencing in a cohort of 500 patients with rare diseases. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2020, 184, 955-964.	0.7	22
29	Sistema imunitÃ¡rio - parte II: fundamentos da resposta imunolÃ³gica mediada por linfÃ³citos T e B. Revista Brasileira De Reumatologia, 2010, 50, 552-580.	0.8	21
30	BehÃ§et Disease. Journal of Clinical Rheumatology, 2011, 17, 416-420.	0.5	20
31	Antiâ€aquaporinâ€4 antibodies in the context of assorted immuneâ€mediated diseases. European Journal of Neurology, 2012, 19, 248-252.	1.7	18
32	Are urinary levels of high mobility group box 1 markers of active nephritis in anti-neutrophil cytoplasmic antibody-associated vasculitis?. Clinical and Experimental Immunology, 2014, 178, 270-278.	1.1	18
33	Absence of mycobacterial DNA in peripheral blood and artery specimens in patients with Takayasu arteritis. Clinical Rheumatology, 2017, 36, 205-208.	1.0	18
34	Understanding BehÃ§etâ€™s Disease in the Context of Innate Immunity Activation. Frontiers in Immunology, 2020, 11, 586558.	2.2	18
35	Cognitive impairment in Brazilian patients with BehÃ§et's disease occurs independently of neurologic manifestation. Journal of the Neurological Sciences, 2013, 327, 1-5.	0.3	17
36	Cutaneous Vasculitis in a Patient with CrohnÊ¼s Disease Treated with Adalimumab. Inflammatory Bowel Diseases, 2017, 23, E1-E2.	0.9	16

#	Article	IF	Citations
37	Impact of Serum High Mobility Group Box 1 and Soluble Receptor for Advanced Glycation End-Products on Subclinical Atherosclerosis in Patients with Granulomatosis with Polyangiitis. PLoS ONE, 2014, 9, e96067.	1.1	15
38	Translation and validation of the Indian Takayasu clinical activity score (ITAS2010) for the Brazilian Portuguese language. Advances in Rheumatology, 2019, 59, 43.	0.8	14
39	A retrospective cohort study to assess PET-CT findings and clinical outcomes in Takayasu arteritis: does 18F-fluorodeoxyglucose uptake in arteries predict relapses?. Rheumatology International, 2020, 40, 1123-1131.	1.5	14
40	Sistema imunitÃ¡rio: parte III. O delicado equilÃbrio do sistema imunolÃ³gico entre os pÃ³los de tolerÃ¢ncia e autoimunidade. Revista Brasileira De Reumatologia, 2010, 50, 665-679.	0.8	13
41	RecomendaÃ§Ãµes da Sociedade Brasileira de Reumatologia para a terapia de induÃ§Ã£o para vasculite associada a ANCA. Revista Brasileira De Reumatologia, 2017, 57, 484-496.	0.8	12
42	Associations between clinical features and therapy with macrophage subpopulations and T cells in inflammatory lesions in the aorta from patients with Takayasu arteritis. Clinical and Experimental Immunology, 2020, 202, 384-393.	1.1	12
43	Epilepsy and BehÃ§et's disease: Cortical and hippocampal involvement in Brazilian patients. Journal of the Neurological Sciences, 2011, 309, 1-4.	0.3	11
44	Lidocaine for systemic sclerosis: a double-blind randomized clinical trial. Orphanet Journal of Rare Diseases, 2011, 6, 5.	1.2	11
45	Retinal angiography and colour Doppler of retrobulbar vessels in Takayasu arteritis. Canadian Journal of Ophthalmology, 2014, 49, 80-86.	0.4	11
46	Recommendations of the Brazilian Society of Rheumatology for the induction therapy of ANCA-associated vasculitis. Revista Brasileira De Reumatologia, 2017, 57, 484-496.	0.7	11
47	Association of anti-glomerular basement membrane antibody disease with dermatomyositis and psoriasis: case report. Sao Paulo Medical Journal, 2010, 128, 306-308.	0.4	10
48	Homocysteine Levels in Takayasu Arteritis â€" A Risk Factor for Arterial Ischemic Events. Journal of Rheumatology, 2013, 40, 303-308.	1.0	10
49	High mobility group box 1 levels in large vessel vasculitis are not associated with disease activity but are influenced by age and statins. Arthritis Research and Therapy, 2015, 17, 158.	1.6	10
50	High mobility group box 1 serum levels are increased in BehÃ§etâ€™s disease, but not associated with disease activity or disease manifestations. Rheumatology, 2015, 54, kev202.	0.9	10
51	Prevalence of cryoglobulinemia and cryoglobulinemic vasculitis in chronically HCV-infected Brazilian patients. Annals of Hepatology, 2019, 18, 685-692.	0.6	9
52	Epidemiologic Features of Systemic Vasculitides in the Southeast Region of Brazil. Journal of Clinical Rheumatology, 2020, 26, S106-S110.	0.5	9
53	18F-Fluorodeoxyglucose positron emission tomography and serum cytokines and matrix metalloproteinases in the assessment of disease activity in Takayasu's arteritis. Revista Brasileira De Reumatologia, 2016, 56, 299-308.	0.7	8
54	Clinical interventions for Takayasu arteritis: A systematic review. International Journal of Clinical Practice, 2017, 71, e12993.	0.8	7

#	Article	IF	Citations
55	The assessment of presenteeism and activity impairment in BehÃ§etâ€™s syndrome and recurrent aphthous stomatitis: a multicentre study. Rheumatology, 2022, 61, 1538-1547.	0.9	6
56	Distribution of monocytes subpopulations in the peripheral blood from patients with BehÃ§et's disease - Impact of disease status and colchicine use. Clinical Immunology, 2021, 231, 108854.	1.4	6
57	Cryopyrin associated periodic syndrome with neurological involvement in a 50â€yearâ€old patient. European Journal of Neurology, 2014, 21, e27-8.	1.7	5
58	Different epidemiologic profiles of systemic vasculitis between Brazil and Peruâ€”preliminary results in two referral centers from both countries. Clinical Rheumatology, 2022, 41, 635-639.	1.0	4
59	Silent arterial inflammation during the apparent remission state of Takayasu's arteritis. What do cytokines tell us?. Clinical and Experimental Rheumatology, 2018, 36 Suppl 111, 33-39.	0.4	4
60	L3. Are mononuclear cells predominant actors of endothelial damage in vasculitis?. Presse Medicale, 2013, 42, 499-503.	0.8	3
61	Transcranial Doppler findings in antiphospholipid syndrome. Lupus, 2019, 28, 483-491.	0.8	3
62	Increased modifiable cardiovascular risk factors in patients with Takayasu arteritis: a multicenter cross-sectional study. Advances in Rheumatology, 2021, 61, 1.	0.8	3
63	Is positron emission tomography/magnetic resonance imaging a reliable tool for detecting vascular activity in treated childhood-onset Takayasuâ€™s arteritis? A multicentre study. Rheumatology, 2022, 61, 554-562.	0.9	3
64	Endothelial progenitor cells and vascular endothelial growth factor in patients with Takayasuâ€™s arteritis. Advances in Rheumatology, 2018, 58, 24.	0.8	2
65	Lower serum levels of transforming growth factor-Î²1 and disease activity in Takayasu arteritis. Scandinavian Journal of Rheumatology, 2020, 49, 161-162.	0.6	2
66	AvaliaÃ§Ã£o da pesquisa de anticorpos antifosfolipÃdios para o diagnÃ³stico da sÃndrome antifosfolÃpide. Revista Brasileira De Reumatologia, 2009, 49, .	0.8	1
67	Editorial: Autoimmune Vasculitis - Advances in Pathogenesis and Therapies. Frontiers in Immunology, 2021, 12, 720257.	2.2	1
68	Search for Autoantibodies in Systemic Vasculitis: Is It Useful?. , 2016, , 29-41.		0
69	HLA-B*51 and its main subtypes in Brazilian patients with BehÃ§et's disease. Clinical and Experimental Rheumatology, 2020, 38 Suppl 127, 53-59.	0.4	0
70	Targeting macrophages in systemic diseases. , 2022, , 279-302.		0